XTAE:BLRX (Israel)  
BioLine Rx Ltd logo

BioLine Rx Ltd

₪ 0.17 (+0.59%) Dec 6
P/E:
At Loss
P/B:
0.83
Market Cap:
₪ 157.81M ($ 46.12M)
Enterprise V:
₪ -243.00K ($ -71.00K)
Volume:
520.54K
Avg Vol (2M):
995.20K
Also Trade In:
Volume:
520.54K
Market Cap ₪:
157.81M
Market Cap $:
46.12M
PE Ratio:
At Loss
Avg Vol (2-Month):
995.20K
Enterprise Value ₪:
-243.00K
Enterprise Value $:
-71.00K
PB Ratio:
0.83
GF Score:
Year:
Not Enough Data to Display
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Not Enough Data to Display
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
BioLine Rx Ltd is a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Its development and commercialization pipeline consists of two clinical-stage therapeutic candidates - Motixafortide, a novel peptide for the treatment of solid tumors, hematological malignancies and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, it has an off- strategy, a legacy therapeutic product called BL-5010 for the treatment of skin lesions.
Name Current Vs Industry Vs History
Cash-To-Debt 5.3
Equity-to-Asset 0.68
Debt-to-Equity 0.2
Debt-to-EBITDA -0.49
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 58.03
9-Day RSI 45.01
14-Day RSI 38.42
6-1 Month Momentum % -36.53
12-1 Month Momentum % -53.41

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 7.12
Quick Ratio 7.12
Cash Ratio 7.04

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -83.9

Financials (Next Earnings Date:2023-03-16 Est.)

XTAE:BLRX's 30-Y Financials

Guru Trades

See Details
To
Not Enough Data to Display

Insider Trades

See Details
To
Not Enough Data to Display

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
Not Enough Data to Display

Performance

Dividend
Log
To
Not Enough Data to Display

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Not Enough Data to Display

Valuation Box

Year:
Not Enough Data to Display

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil ₪)
EPS (TTM) (₪) -0.102
Beta 0
Volatility % 43.86
14-Day RSI 38.42
14-Day ATR (₪) 0.010905
20-Day SMA (₪) 0.16965
12-1 Month Momentum % -53.41
52-Week Range (₪) 0.157 - 0.579
Shares Outstanding (Mil) 922.87

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

BioLine Rx Ltd Filings

Document Form Filing Date
No Filing Data

BioLine Rx Ltd Analysis

Share your research